General Neurology
Brain death/death by neurologic criteria
Nov. 09, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Visual hallucinations in blindness …
- Updated 05.01.2024
- Released 04.20.2013
- Expires For CME 05.01.2027
Visual hallucinations in blindness
Introduction
Overview
In this article, the author explains the clinical presentation, pathophysiology, diagnostic workup, and management of visual hallucinations in blindness. Bonnet syndrome (sometimes referred to as Charles Bonnet syndrome) most commonly refers to visual hallucinations in visually impaired individuals with full alertness, unimpaired cognition, and no psychosis. Although Bonnet syndrome is most commonly identified in patients with bilaterally decreased central visual acuity, similar phenomena also occur in patients with retrochiasmal visual field defects. Bonnet hallucinations are thought to result from a "release" mechanism associated with modality-specific sensory deprivation, ie, "phantom vision" akin to phantom limbs in patients with loss of somatosensory input after an amputation. Although there is no definitive treatment available for Bonnet syndrome, various ophthalmologic interventions, behavioral strategies, and pharmacologic agents have been used to try to reduce or relieve symptoms.
Key points
|
• Bonnet syndrome (sometimes called Charles Bonnet syndrome) is now generally considered to refer to visual hallucinations in visually impaired individuals with full alertness, unimpaired cognition, and no psychosis. | |
|
• These hallucinations can include simple or complex hallucinations, including geometric shapes, animals ("zoopsias"), human figures, buildings, or landscape scenes. | |
|
• Bonnet hallucinations are usually well-defined and clear, often elaborate, visual hallucinations restricted to a single modality, ie, visual hallucinations only without associated olfactory, gustatory, auditory, or tactile hallucinations. | |
|
• Patients generally have full or partial retention of insight, without delusions or psychosis and without associated intoxication or withdrawal. | |
|
• Bonnet syndrome frequently goes unrecognized in clinical practice due to providers’ lack of awareness and patients' reluctance to report hallucinatory experiences. Many elderly patients with such hallucinations are concerned that these indicate mental illness or the incipient development of dementia. | |
|
• Although Bonnet syndrome is most commonly identified in patients with bilaterally decreased central visual acuity, similar phenomena also occur in patients with retrochiasmal visual field defects. | |
|
• Bonnet hallucinations are thought to result from a "release" mechanism associated with modality-specific sensory deprivation, ie, "phantom vision" akin to phantom limbs in patients with loss of somatosensory input after an amputation. | |
|
• Although no definitive treatment is available for Bonnet syndrome, various ophthalmologic interventions, behavioral strategies, and pharmacologic agents have been used to reduce or relieve symptoms. |
Historical note and terminology
Bonnet syndrome. In the late 18th century, Charles Bonnet reported visual hallucinations in cognitively normal elderly persons (ie, in Bonnet's 89-year-old grandfather Charles Lullin and, later, in Bonnet himself) (11; 09; 34; 62; 53).
In 1936, de Morsier eponymously recognized Bonnet's report and designated Bonnet syndrome as a syndrome of visual hallucinations in elderly persons with ocular lesions and intact cognition (30; 38). Three decades later, de Morsier tried to remove ocular disease from the syndromic definition and considered Bonnet hallucinations as visual hallucinations occurring among the elderly with intact cognition, regardless of etiology (31).
Bonnet syndrome (sometimes referred to as Charles Bonnet syndrome) is now most commonly considered to refer to visual hallucinations in visually impaired individuals with full alertness, unimpaired cognition, and no psychosis (and this is the operational definition used for this article) (44; 123; 144; 143; 124; 08; 82; 88; 38; 20; 85; 34; 62; 153; 21; 96). Other definitions are also employed, however, which leads to confusion and confounds clarification of the pathophysiology of the disorder (102; 48): indeed, because of the varying definitions, a number of authors have argued that the eponym is no longer useful (108; 17). For example, some authors accept as Bonnet hallucinations cases with unformed visual hallucinations (photopsias) (17; 153; 01; 70), cases with dementia or other cognitive impairment (147), or cases with epileptic visual hallucinations (93; 15), whereas others restrict cases to elderly patients, to patients with complex formed visual hallucinations, or to cases with prechiasmal visual impairment (23; 38; 145).
James Thurber and Bonnet syndrome. In Phantoms in the Brain: Probing the Mysteries of the Human Mind (1998), psychologist and neuroscientist Vilayanur Ramachandran MBBS PhD suggested that the American author, humorist, and cartoonist James Thurber (1894–1961) had Bonnet syndrome (105; 54).
When Thurber was 6 years old, his older brother, William, accidentally shot an arrow into his left eye, reportedly while playing “William Tell.” His injured eye was not immediately removed, and vision in Thurber’s undamaged right eye soon became impaired because of sympathetic ophthalmia. Sympathetic ophthalmia is a bilateral, granulomatous uveitis that can occur after trauma to one eye, presumably due to an autoimmune mechanism. The condition is vision-threatening, and many patients end up with significant bilateral vision loss, especially if treatment is not instituted quickly. Prevention is limited to urgent closure of the traumatized eye and enucleation within 10 to 14 days after the traumatic event. Thurber’s injured left eye was eventually removed, but by then, vision in his uninjured right eye was also permanently impaired, and he was going blind by 1937.
Ramachandran wrote that as an adult with severe visual impairment, Thurber described numerous vivid visual hallucinations in correspondence with his ophthalmologist:
|
• “I saw bridges rise lazily into the air, like balloons.” | |
|
• “I saw a cat roll across a street in a striped barrel.” | |
|
• “I saw an old woman with a gray parasol walk right through the side of a truck.” |
These visual hallucinations in the setting of severely impaired vision in an otherwise mentally healthy person are consistent with Bonnet hallucinations. Ramachandran further suggested that Thurber's vivid imagination may be partly explained by having had Bonnet syndrome.
Clinical manifestations
Presentation and course
• Bonnet hallucinations can include simple or complex hallucinations, including geometric shapes, animals ("zoopsias"), human figures, buildings, or landscape scenes. | |
• Bonnet hallucinations are usually well-defined and clear; complex; and often elaborate, repetitive, stereotyped visual hallucinations restricted to a single modality, ie, visual hallucinations only without associated olfactory, gustatory, auditory, or tactile hallucinations. They may appear suddenly, are not under voluntary control, are persistent though usually intermittent, and are simultaneous bilateral phenomena. The most common hallucinations are of people or animals. | |
• Patients generally have full or partial retention of insight, without delusions or psychosis and without associated intoxication or withdrawal. | |
• Bonnet syndrome frequently goes unrecognized in clinical practice due to providers’ lack of awareness and patients' reluctance to report hallucinatory experiences. | |
• Although Bonnet syndrome is most commonly identified in patients with bilaterally decreased central visual acuity, similar phenomena also occur in patients with retrochiasmal visual field defects. |
From a definitional perspective, patients with phosphenes (ie, unstructured lights such as flashes, sparkles, zig-zag lines), photopsias (ie, simple structured images such as geometric figures occurring in a repetitive pattern), and complex visual hallucinations (eg, people, animals, landscapes) have similar lesions on brain imaging (150), suggesting that there is no anatomic area unique for each type of "positive spontaneous visual phenomena." Thus, limiting the definition of Bonnet hallucinations to complex visual hallucinations has no clear localizing value or etiologic specificity (115; 17; 153). As a result, most now accept that these hallucinations can include simple or complex hallucinations, including geometric shapes, animals ("zoopsias"), human figures, buildings, or landscape scenes (122; 23; 08; 82; 125; 115; 86; 41; 70).
Bonnet hallucinations are usually well-defined and clear, complex and often elaborate, repetitive, stereotyped visual hallucinations restricted to a single modality, ie, visual hallucinations only without associated olfactory, gustatory, auditory, or tactile hallucinations (66). They may appear suddenly, are not under voluntary control, are persistent though usually intermittent, and are simultaneous bilateral phenomena (14). The hallucinations may be stationary or in motion (125; 70; 116), altered in size (eg, small or "Lilliputian" figures), sometimes grotesque or distorted (115), and are frequently chromatic (colored, and often multicolored) (142; 82; 92; 153; 70; 14). The most common hallucinations are of people or animals (70; 116).
Patients generally have full or partial retention of insight, without delusions or psychosis, and without associated intoxication or withdrawal (66). The hallucinations are generally neutral or pleasant and nonthreatening but may cause distress, especially as patients are aware that the visual images are not "real" (122; 23; 143; 142; 146; 08; 125; 85; 137; 138; 153; 151; 27; 113; 112). The content of the hallucinations has no personal meaning for affected patients (144). Nevertheless, the emotional response to the hallucinations is typically congruent with the hallucinatory content; for example, hallucinations of a macabre nature typically produce a fearful response (64). Factors associated with negative outcomes include: (1) frequent, fear-inducing, longer-duration hallucinations; (2) evident impact on daily activities; (3) misattribution of hallucinations to mental illness; and (4) inadequate knowledge of Bonnet syndrome at symptom onset (27).
The frequency of Bonnet hallucinations may range from daily to weekly (92; 116; 149), and the duration of individual hallucinations is usually a few minutes but may be shorter or longer, from seconds up to a full day (122; 124; 08; 92; 116; 149). Episodes can occur for days to years, with changes in complexity and frequency over time (122; 116). However, most episodes last days to months (150).
Triggers for Bonnet hallucinations can include low light levels, fatigue, and emotional stress (122; 142). Bonnet hallucinations often occur with eyes open and disappear with eyes closed. Some patients can terminate their hallucinations by closing or opening their eyes, attempting to fixate vision on or away from the hallucination, or making saccades to one side or the other (72; 142; 150).
Bonnet syndrome frequently goes unrecognized in clinical practice due to providers’ lack of awareness and patients' reluctance to report hallucinatory experiences (43; 151). Some patients are afraid to report such hallucinations to their physicians because they are concerned that these indicate mental illness or the incipient development of dementia, and, therefore, that reporting such experiences will compromise their autonomy (64). Many affected patients express relief when informed that such hallucinations are relatively benign and unrelated to insanity or dementia.
Patients with progressive bilateral prechiasmal visual loss often develop Bonnet hallucinations as visual acuity declines, but these hallucinations typically resolve after development of total blindness (128; 43). At least in some patients, an acute or subacute reduction in visual acuity appears to be more important than static low visual acuity per se (128). In patients with age-related macular degeneration, the extent of visual loss does not predict the likelihood of developing Bonnet syndrome, nor does the progression of loss reflect in the complexity of the hallucinations reported (01).
Although Bonnet syndrome is most commonly identified in patients with bilaterally decreased central visual acuity (104), similar phenomena also occur in patients with retrochiasmal visual field defects (16; 123; 41; 21; 40; 139; 05; 25; 68; 19; 74; 118), and even in patients with visual field defects and normal central visual acuity (41; 139; 81). Bonnet hallucinations in patients with retrochiasmal visual field defects occur most commonly in patients with cerebral infarcts involving the optic radiations or primary visual cortex but may also occur in other circumstances, eg, after antero-mesial temporal lobe resection for epilepsy (25), or with occipital falx meningiomas (118). Visual hallucinations are typically restricted to the abnormal visual field in patients with visual field defects. Retrochiasmal lesions associated with hallucinations are typically smaller than those causing hemianopsia without associated Bonnet hallucinations and frequently spare visual association cortex, whereas large lesions destroying anterior visual association cortex appear to preclude development of such hallucinations, suggesting that some intact visual association cortex is necessary to experience these complex hallucinations (150). Onset in central cases is generally within a few days of the event causing the defect (72).
A similar phenomenon may be responsible for visual hallucinations in the Heidenhain variant of Creutzfeldt-Jakob disease, which is characterized by isolated visual disturbances at disease onset, including complex visual hallucinations, which reflect the early involvement of prions in the occipital cortex (95; 12; 103; 45; 114; 148; 133; 154).
The relationship between Bonnet syndrome and cognition is not entirely clear because some elderly patients with Bonnet syndrome subsequently develop dementia. In a pilot cohort study of people over age 65 with Bonnet syndrome and age-matched controls, two of 12 cases and no controls developed dementia (113). Both cases that developed dementia had partial insight and hallucinations of familiar figures at the time of diagnosis of Bonnet syndrome, and one had mild cognitive impairment. Further larger cohort studies will be needed to determine whether elderly patients with Bonnet syndrome have an increased risk of developing dementia.
Prognosis and complications
Bonnet syndrome has a significant negative association with vision-related quality of life (106).
Postsurgical cases are generally transient and resolve between 4 days and 6 months postoperatively, even with persisting visual field deficits (41; 25). Because of the benign nature of the phenomena, and the self-limited course, such postoperative hallucinations do not usually require treatment (25).
Some have suggested that Bonnet syndrome may be an early marker for dementia (101; 50), though most studies do not indicate any cognitive impairment in most patients with Bonnet syndrome (10; 123; 147).
Systematic longitudinal cognitive evaluations on large samples of patients with Bonnet syndrome have yet to be performed. Preliminary data suggest that the hallucinations will resolve within 1 year in more than a quarter of those who develop Bonnet hallucinations (60).
Clinical vignette
Case 1. Visual hallucinations after resection of cerebral metastasis (94). A 74-year-old man presented with a right homonymous hemianopia and persistent left-temporal headache. Four years previously, he was diagnosed with adenocarcinoma of the cardia (ie, the portion of the stomach that is closest to the esophagus), which was treated conservatively with systemic paclitaxel and ramucirumab. Neurologic examination revealed an incomplete right homonymous hemianopia and preexisting hypoesthesia of the lower extremities attributed to paclitaxel-induced polyneuropathy. Cranial MRI revealed a 4 cm paramedian space-occupying lesion in the left occipital lobe. On T2-weighted sequences, the lesion was iso- to hypointense. On T1-weighted images, a hypointense, partially cystic mass with marginal contrast enhancement and pronounced perilesional edema extending into the perisplenial, temporal, and parietal regions up to 4 cm distant to the lesion was visible. The radiological findings were interpreted as an occipital lobe metastasis and a possible cause of his visual deficits. Neurosurgical resection was performed without surgical complications. Histology showed an adenocarcinoma metastasis. Postoperative hypofractionated stereotactic radiotherapy was applied to the surgical cavity with a 2 mm margin.
-
Case timeline in right homonymous hemianopia and persistent left-temporal headache
Case timeline for a 74-year-old man who presented with a right homonymous hemianopia and persistent left-temporal headache. (Source: Ovchinnikov A, Andereggen L, Rogers S, Gschwind M. Visual hallucinations after resection of ce...
-
Slightly hypointense, ring-enhancing, and partially cystic mass with marked perilesional edema
Sagittal T1-weighted contrast-enhanced MRI at time of diagnosis shows a slightly hypointense, ring-enhancing, and partially cystic mass with marked perilesional edema. There was a minor midline shift. (Source: Ovchinnikov A, An...
After surgery, the patient mentioned repetitive hallucinations predominantly in the right visual field. They occurred daily, lasting for a few seconds, with no change in the level of consciousness or other events suspicious for seizures. The patient recurrently saw visual images from his past (eg, his father, grandfather, or his dog standing in the room) in the right visual field. He also reported visual perseveration of a previously seen image (palinopsia) and deformation of central vision (metamorphopsia). Initially, the hallucinations were attributed to epileptic seizures, and he was started on antiepileptic therapy with levetiracetam. However, an electroencephalogram did not reveal any epileptogenic activity. The anticonvulsive therapy was gradually discontinued, with no effect on the recurrent hallucinations.
Three months after neurosurgery, the patient reported a slight reduction in the intensity of brief daily hallucinations. His right-sided hemianopia (predominantly in the upper quadrant with visual neglect to the right) persisted. During examination, the patient reported a brief hallucination in his right visual field (he saw his grandfather for several seconds) and no additional symptoms could be observed, especially no qualitative or quantitative disturbance of consciousness. The latest EEG without antiepileptic treatment showed regional slowing in the left parieto-occipital region consistent with his tumor resection but no evidence of epileptogenic activity. Follow-up MRI 4 months postoperatively showed no signs of tumor recurrence, and the patient reported no recent hallucinations at clinical follow-up 18 months after metastasectomy.
Case 2. Visual hallucinations after occipital lobe infarction (136). A 73-year-old Asian man, independent in activities of daily living, presented with right homonymous hemianopsia and episodes of forgetfulness. Cranial imaging revealed an acute left occipital lobe infarct consistent with an embolic etiology. He was prescribed edoxaban (a direct oral anticoagulant) and discharged with residual right homonymous hemianopsia. Two weeks after symptom onset, he experienced visual hallucinations characterized as silhouettes and shapes of individuals and objects on the side of visual loss. Psychiatric history was unremarkable. Past medical history included hypertension and dyslipidemia. He denied alcohol intake or illicit drug use.
On neurologic examination, the patient reported perceiving the outline of a person in motion, confined to the region of visual loss. He was aware that these hallucinations were not real and that they did not pose any harm to him. A right homonymous hemianopsia was evident on the visual confrontation testing. His Montreal Cognitive Assessment - Philippines (MoCA-P) score of 20/30 was consistent with mild cognitive impairment. Visual acuity was 20/70 in the right eye and 20/100 in the left eye. Visual perimetry test confirmed his right homonymous hemianopsia. Laboratory evaluation revealed an elevated serum creatinine level [137 μmol/L (reference range 49.0-115.0 μmol/L)] but was otherwise unremarkable.
Cranial MRI showed hemorrhagic conversion of the left occipital lobe infarct. An electroencephalogram showed focal and intermittent slowing of the anterior temporal and frontal region, with no interictal epileptiform discharges. He was discharged on levetiracetam and edoxaban. On follow-up after 2 weeks, his visual field loss was improved and was then limited to a right homonymous superior quadrantanopsia by visual confrontation testing. Concomitant with his improved visual fields, he experienced a decrease in the frequency of the visual hallucinations (2 to 3 times/week on the side of visual field loss).
Biological basis
• Bonnet hallucinations are caused by bilateral blindness, usually a severe to profound loss, most commonly related to retinal disease, usually age-related macular degeneration and glaucoma. | |
• The complex nature of Bonnet hallucinations indicates that they are generated in the visual association cortex. | |
• In support of a release mechanism for Bonnet hallucinations, sensory deprivation and a low level of arousal favor development of the hallucinations but are not required for their development. | |
• In general, a "release" mechanism for hallucinations is supported by (1) a sensory deficit in the same modality as unimodal hallucinations, with onset of hallucinations in conjunction with or following the sensory deficit; (2) variable content; (3) awareness of the hallucinatory nature of the perception; and (4) no evidence of seizures or other irritative phenomena (including no other positive motor or sensory phenomena, not paroxysmal in character, and no epileptiform discharges on electroencephalography). |
Etiology and pathogenesis
Bonnet hallucinations are caused by bilateral blindness, usually a severe to profound loss, typically related to retinal disease, usually age-related macular degeneration and glaucoma (116; 90). Other causes of blindness can also produce Bonnet hallucinations, including retinitis pigments, anterior ischemic optic neuropathy, toxoplasmic retinochoroiditis, pituitary lesions involving the chiasm, etc. (149; 06). Related phenomena are caused by homonymous visual field defects resulting from interruption of visual input to the occipital cortex from various causes, including infarcts (136), malignancies (or following their resection) (94), demyelination, posterior reversible encephalopathy syndrome (PRES) (32; 52; 156), the Heidenhain variant of Creutzfeldt-Jakob disease (73; 12; 45), and probably some cases of Anton syndrome.
The complex nature of Bonnet hallucinations indicates that they are generated in the visual association cortex (41). The development of visual hallucinations in patients with hemianopia after stroke is inversely correlated with lesion size and specifically requires a relatively small lesion that includes loss of the striate cortex but that spares Brodmann areas 19, 20, and 37 (83).
Visual pathway lesions can cause hallucinations from defective visual processing or abnormal cortical activity (82). The specific pathophysiological mechanisms involved in Bonnet syndrome are still being investigated, but many authors have suggested a "release" mechanism associated with modality-specific sensory deprivation or deafferentation (130; 122; 123; 17; 86; 85; 41; 104; 21; 139; 61; 18). Some have referred to this as "phantom vision" akin to phantom limbs in patients with loss of somatosensory input after an amputation (122; 91; 85). In support of a release mechanism for Bonnet hallucinations, sensory deprivation and a low level of arousal favor development of the hallucinations but are not required for their development (142). It may occur even with transient vision loss, as with eye patching, in susceptible individuals (61).
Cogan distinguished "irritative" and "release" hallucinations in patients without psychosis (22). An "irritative" mechanism for hallucinations is supported by any of the following: (1) stereotyped content; (2) lack of awareness of the hallucinatory nature of the perception ("hallucinosis"); and (3) evidence of an irritative process (eg, migraine, tumor, seizures) (22; 13). In general, a "release" mechanism for hallucinations is supported by (1) a sensory deficit in the same modality as unimodal hallucinations, with onset of hallucinations in conjunction with or following the sensory deficit; (2) variable content; (3) awareness of the hallucinatory nature of the perception; and (4) no evidence of seizures or other irritative phenomena (including no other positive motor or sensory phenomena, not paroxysmal in character, and no epileptiform discharges on electroencephalography) (22; 79; 13). Release hallucinations can occur in normal individuals with pansensory deprivation (57; 56). Similarly, modality-specific release hallucinations can occur experimentally (56; 84) or pathologically (55; 79; 78) with unimodal sensory deprivation. In support of a release mechanism for Bonnet hallucinations, sensory deprivation and a low level of arousal favor development of the hallucinations but are not required for their development (142).
Presumably, a generative model exists in the brain that can synthesize consistent visual representations even without actual visual input (111). Homeostatic regulation of neuronal activity could make the learned internal model robust against degradation of sensory input, but it may overcompensate in the case of Bonnet syndrome, leading to hallucinations (111).
Deafferentation produces an increase in excitability of the deafferentated neurons and an increase in spontaneous activity (33; 76; 35; 17). High-frequency bursts of synchronized though nonepileptic neural activity in areas of deafferentated cortex may be necessary for these hallucinations (17).
SPECT studies of patients with Bonnet syndrome have shown hyperperfusion in the lateral temporal cortex, striatum, and thalamus, presumably representing the results of central nervous system plasticity and compensation (02). In one case, positron emission tomography-statistical parametric mapping studies initially showed hypermetabolism in the right inferior temporal area and left thalamus, which disappeared after treatment with valproic acid (63). Functional magnetic resonance imaging studies indicate that Bonnet hallucinations are associated with increased ventral extrastriate activity, which persists even between hallucinations (39). The location of increased activity correlates with the type of hallucination, with color associated with activity in the posterior fusiform area, faces associated with activity in the left middle fusiform area, objects associated with activity in the right middle fusiform area, and textures associated with the collateral sulcus (39). The relative frequency of certain complex forms (eg, faces) may reflect the amount of association cortex devoted to representing these forms or the magnitude of the distributed network processing such forms (76; 153).
An informative case was presented by Sasaki and colleagues (118). A 74-year-old man presented with complex visual hallucinations with a left inferior quadrantanopia, due to a right occipital falx meningioma. Fusion images of gadolinium-enhanced MRI and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) of the brain demonstrated hypometabolism in the right primary and secondary visual cortices and an ipsilateral hypermetabolism in a focal area of the medial aspect of the secondary visual cortex as well as the lateral part of the ventral visual pathway. Presumably, this hyperactivation of the ventral visual pathway, especially the lateral aspect of the ventral occipitotemporal cortex, was "released" by the inactivity of the corresponding primary visual cortex due to mass effect from the meningioma. In some cases, transient dynamic changes in visual acuity can precipitate or relieve the hallucinations. Bonnet hallucinations have been reported during visual recovery after central retinal artery occlusion (140). Acute severe anemia can precipitate worsened vision and Bonnet hallucinations in some patients (eg, bilateral retinal vein occlusion), and rapid visual acuity improvement and reversal of hallucinations may follow blood transfusion (67). Bonnet hallucinations may occur even with transient loss of vision, as with eye patching, in susceptible individuals (69; 61).
A variant disorder, labeled the "Charles Bonnet plus syndrome" or "Charles Bonnet syndrome plus," involves multimodal hallucinations resulting from deafferentation in more than one sensory modality. For example, a patient with Usher syndrome (a genetic syndrome characterized by progressive loss of vision and hearing) experienced complex visual hallucinations and musical auditory hallucinations ("cabaret music") (127).
Perception models relevant to Bonnet syndrome. Perception arises through an interaction between sensory input and prior knowledge (42; 26; 121). Predictive processing models posit that the brain generates a model of the world and makes predictions about future states, predictions are compared to actual sensory input and a prediction error is calculated, and the model is updated, or actions are undertaken, to minimize the prediction error (121). Predictive processing theories hold that our subjective experience of reality is shaped by a balance of expectations based on previous knowledge of the environment (ie, "priors") and confidence in sensory input from the environment (110; 121). Strong prior beliefs ("strong priors") are important ("a critical eliciter”) in the genesis of hallucinations because they lead to a misinterpretation of spontaneous activity as actual sensory input (26; 121). Selective attention modifies activity in early visual processing areas specific to the attended feature (42). Early visual processing areas can also be modified (1) when prior knowledge permits a percept to emerge from an otherwise meaningless stimulus, and (2) based on prior knowledge about the predicted sensory effects of the subject's own actions (42). Hallucinations are likely to occur when there is an imbalance between one's reliance on priors and sensory input (110). A study of patients with Lewy body disease suggests that their visual hallucinations result from a shift towards top-down influences on perception and away from sensory evidence, perhaps due to an increase in sensory noise (155). Similarly, damage to sensory processing areas can lead to a form of sensory hallucination, so-called "release hallucinations," which arise from the interaction of prior knowledge with random sensory activity (42).
In a carefully controlled functional MRI study, Bonnet syndrome participants demonstrated a slow build-up of neural activity prior to the reported onset of hallucinations (47). The build-up of neural activity was most pronounced in early visual cortex and then decayed along the visual hierarchy. In the absence of external visual input, a build-up of spontaneous fluctuations in early visual cortex may activate the later visual processing areas, thereby triggering the experience of vision.
Challenges have been made to existing predictive processing models of complex visual hallucinations that are relevant to Bonnet and other types of visual hallucinations (24; 121). Current models of visual hallucinations (ie, Deafferentation, Reality Monitoring, Perception and Attention Deficit, Activation, Input, and Modulation, Hodological, Attentional Networks, Active Inference, and Thalamocortical Dysrhythmia Default Mode Network Decoupling) were derived from different understandings of brain organization and also to account for different types of hallucinations across a range of clinical conditions (24). An attempt has been made to provide a "harmonized framework" for such visual processing models to allow comparison of the strengths and weaknesses of different models. This framework can be used to establish a deafferentation model applicable to Bonnet syndrome.
-
Harmonized framework for aspects of visual perception relevant to hallucinations
Descending influences are shown in blue, and ascending are shown in red. Horizontal influences are in green. The grey blur over memory, context, emotion, and intention indicates that these factors interact to create complex exp...
-
Harmonized framework used to establish a deafferentation model applicable to Bonnet syndrome
The functional mechanism under deafferentation (ie, blindness in this context) is that false sensory data become overly influential, overriding the results of data comparison and expectancies to become incorporated into a hallu...
Nevertheless, although deafferentation remains the best available pathophysiological explanation for Bonnet hallucinations, deafferentation alone seems insufficient as it fails to explain the absence of hallucinations in most patients with severe bilateral visual impairment (37).
Epidemiology
|
• Estimates of the prevalence of Bonnet syndrome range widely in different samples depending on the distribution of severe bilateral vision loss in the group studied and the specific disease definition or diagnostic criteria. | |
|
• Among general ophthalmologic and optometric patients, the frequency is about 0.5% but higher in patients with low vision and the elderly. | |
|
• Higher rates are seen in patients with severe glaucoma, macular degeneration, or other low vision caused by anterior visual pathway dysfunction and in postoperative patients following lesions of the retrochiasmal visual pathways. | |
|
• The prevalence of Bonnet syndrome in patients with late age-related macular degeneration is high, with estimates of 8% to 58%. |
Visual dysfunction is associated with an increased likelihood of hallucinations in the older U.S. adult population: hallucinations are more prevalent in those with difficulty reading newspaper print or recognizing someone across the street (49).
Estimates of the prevalence of Bonnet syndrome range widely in different samples depending on the distribution of severe bilateral vision loss in the group studied and the specific disease definition or diagnostic criteria (143; 92; 41; 129; 116; 119). Among general ophthalmologic and optometric patients, the frequency is about 0.5% (129), but higher in patients with low vision and the elderly (143; 129; 70; 59; 116). Higher rates are seen in patients with severe glaucoma (92; 66; 99), macular degeneration (70; 116; 66), or other low vision caused by anterior visual pathway dysfunction (143; 152; 66), and in postoperative patients following lesions of the retrochiasmal visual pathways (41). In a meta-analysis, the prevalence of Bonnet syndrome was 2.8% among patients with glaucoma in different stages and with ocular comorbidities, 13.5% among patients with glaucoma and bilateral low visual acuity, and 20.1% among patients with glaucoma who visited vision rehabilitation clinics, presumably due to extensive vision impairment (135). The prevalence of Bonnet syndrome in patients with late age-related macular degeneration is high, with estimates of 8% to 58% (70; 151; 132; 116; 80). Similar values are reported in other populations of elderly patients with severe bilateral vision loss (152). Prevalence does not differ significantly by the cause of the visual problem when patients of similar age and degree of visual impairment are compared (43).
Besides low vision, risk factors for (a diagnosis of) Bonnet syndrome include advanced age, female gender, reduced contrast sensitivity, and not living alone (135).
Bonnet syndrome frequently goes unrecognized in clinical practice due to a lack of awareness among providers and patients' reluctance to report hallucinatory experiences for fear of being labeled as mentally ill (130; 142; 92; 85; 137; 27; 149).
Although most cases are elderly, Bonnet hallucinations may also occur in children and adolescents (65). Most of these have progressive inherited retinal diseases, primarily Stargardt disease, a rare genetic eye disease associated with deposition of fatty material in the macula (65). Mutations in the ABCA4 gene usually cause Stargardt macular degeneration, but, less often, it may be caused by mutations in the ELOVL4 gene. Other reported pediatric disorders can also cause this, including juvenile neuronal ceroid lipofuscinosis (78).
Poor visual acuity is the most important factor associated with developing of Bonnet hallucinations (70). Although Bonnet hallucinations can affect people of any age, including children (117), it is much more common in elderly patients (143; 08; 38; 02; 20; 85; 62; 100; 129; 138; 21; 01; 71). Medications, such as proton-pump inhibitors, can increase the risk of developing visual hallucinations independently of the degree of visual loss in patients with age-related macular degeneration (80).
Differential diagnosis
Confusing conditions
The differential diagnosis of visual hallucinations is broad. In the elderly, who are most susceptible to Bonnet hallucinations, visual hallucinations are commonly reported in the absence of significant visual impairment in patients with psychosis, medication-induced hallucinosis, delirium, delirium tremens, Parkinson disease, Lewy body dementia, and Alzheimer disease.
The main consideration is separating visual hallucinations associated with bilateral visual loss (Bonnet hallucinations) from visual hallucinations associated with psychiatric disorders, delirium, or dementia. Cognitive impairment alone can be associated with visual hallucinations, even without visual impairment. It seems likely, though, that cognitive impairment can facilitate the development of visual hallucinations in those with visual impairment (and vice versa) (52; 75). Visual hallucinations are commonly observed in patients with synucleinopathies such as Parkinson disease and Lewy body dementia; in these disorders, the visual hallucinations result from a combination of the underlying pathology as well as the dopaminergic medications used to treat these disorders.
A few authors have also reported what were labeled as Bonnet hallucinations following administration of a medication, which then resolved on medication withdrawal; however, these are probably cases of medication-induced visual hallucinosis, and in general, such cases should not be considered as cases of Bonnet syndrome.
Patients with retrochiasmal visual pathway dysfunction (eg, homonymous hemianopsia), who develop intermittent complex visual hallucinations, may instead have partial seizures (93; 15). Although some authors have considered epileptic visual hallucinations as an epileptic form of Bonnet syndrome (93; 15), this is conceptually problematic, and such terminology should be discouraged.
Diagnostic workup
|
• Although the diagnostic evaluation is usually straightforward in Bonnet hallucinations, they remain commonly underreported, underrecognized, and misrecognized. | |
|
• Visual hallucinations in conjunction with significant bilateral visual loss should raise clinical suspicion for Bonnet hallucinations. | |
|
• With history and examination, it will often be possible to establish a localization for the visual loss and a specific etiologic diagnosis. | |
|
• Neuroimaging is often needed to establish or support an etiologic diagnosis with retrobulbar visual loss localized to the optic nerves (eg, demyelinating disease), optic chiasm (eg, pituitary tumors), or retrochiasmal visual pathways (eg, cerebrovascular disease). |
Although the diagnostic evaluation is usually straightforward in Bonnet hallucinations, they remain commonly underreported, underrecognized, and misrecognized (66). Visual hallucinations in conjunction with significant bilateral visual loss should raise clinical suspicion for Bonnet hallucinations. The visual loss should then be localized to the eyes, optic nerves (07), chiasm (100; 59), or retrochiasmal visual pathways based on ophthalmoscopy, pupillary reactions, and visual fields. With history and examination, establishing a localization for the visual loss and a specific etiologic diagnosis will often be possible. Ophthalmology referral is appropriate for patients with ocular pathology (eg, cataracts, glaucoma, macular degeneration, diabetic retinopathy). Neuroimaging is often needed to establish or support an etiologic diagnosis with retrobulbar visual loss localized to the optic nerves (eg, demyelinating disease), optic chiasm (eg, pituitary tumors), or retrochiasmal visual pathways (eg, cerebrovascular disease). Further evaluation is dictated by the history, the identified locus of the visual impairment, and the results of neuroimaging.
Management
|
• There is no definitive treatment available for Bonnet syndrome, although various ophthalmologic interventions, behavioral strategies, and pharmacologic agents have been used to try to reduce or relieve symptoms. | |
|
• Bonnet hallucinations may terminate spontaneously, on improving or stabilizing visual loss (eg, with glasses, cataract surgery, laser treatments, low-vision devices, etc., as appropriate to the clinical circumstances), with use of improved lighting, or on improving grief, loneliness, or social isolation. | |
|
• Patients are often afraid to report such hallucinations to their physicians because they are concerned that these indicate mental illness or development of dementia; therefore, reassurance is one of the mainstays of treatment. | |
|
• A wide range of pharmacological treatments have also been reported to alleviate Bonnet hallucinations, but almost all of these are anecdotal, being based on small samples (often single cases) in uncontrolled trials. |
Patients and their families generally respond favorably to education concerning the nature of the hallucinations and supportive counseling. It is important to emphasize that the phenomenon is common, benign, related to visual impairment, and not indicative of dementia, psychosis, or serious underlying neurologic disease.
There is no definitive treatment available for Bonnet syndrome, although various ophthalmologic interventions, behavioral strategies, and pharmacologic agents have been used to try to reduce or relieve symptoms (51).
Bonnet hallucinations may terminate spontaneously, on improving or stabilizing of visual loss (eg, with glasses, cataract surgery, laser treatments, low-vision devices, etc., as appropriate to the clinical circumstances), with use of improved lighting, or on improving grief, loneliness, or social isolation (04; 144; 146; 08; 141; 85; 34; 62; 28; 131). Treatment, therefore, should focus initially on correcting visual function, using adaptive equipment as necessary, as well as ensuring adequate lighting and increasing social interaction and engagement (28; 120; 131).
Some patients are afraid to report such hallucinations to their physicians because they are concerned that these indicate mental illness or development of dementia (92; 85; 137; 153; 151; 89). Reassurance is, therefore, one of the mainstays of treatment (120). Many patients with Bonnet hallucinations express relief when informed that such hallucinations are relatively benign and unrelated to insanity or dementia (142; 08; 62; 137; 120).
In some cases, medications seem to precipitate the hallucinations, and such hallucinations respond to withdrawal of the medications (36; 145; 126). However, it is often unclear if these are simply cases of medication-induced visual hallucinosis (104) and should not generally be considered cases of Bonnet syndrome. A different circumstance occurs when Bonnet hallucinations develop in patients with severe age-related macular degeneration after intravitreal injections of bevacizumab (an angiogenesis inhibitor): in such cases, reduced retinal edema and temporarily altered visual acuity may promote the release phenomenon and trigger Bonnet hallucinations (87).
A wide range of pharmacological treatments have also been reported to alleviate Bonnet hallucinations, but almost all of these are anecdotal, being based on small samples (often single cases) in uncontrolled trials (34). There is no universally effective drug treatment (08; 85). Such hallucinations are generally not resolved or improved with anticonvulsants or antipsychotic medications (08; 34; 21), although there are anecdotal reports of occasional patients that seem to respond to anticonvulsants, atypical antipsychotic medications, or selective serotonin reuptake inhibitors (08; 107; 58; 03; 85; 34; 98; 77; 126; 19; 46). Other agents have been anecdotally reported to be effective in isolated patients, including acetylcholinesterase inhibitors (147). In rare cases of Bonnet syndrome associated with visual impairments from temporal arteritis, steroid treatment can result in prompt resolution of visual hallucinations, even with persistent visual loss (134; 109); the implications of this are not fully clear but may suggest other mechanisms may be involved in the continuation of such hallucinations beyond simple "release" mechanisms. Tricyclic antidepressants and benzodiazepines have not been helpful (08).
Outcomes
More complicated interventions have also been explored in pilot studies, including inhibitory transcranial direct current stimulation of the visual cortex (29), but this has not been proven with adequate controlled trials.
Media
References
- 01
- Abbott EJ, Connor GB, Artes PH, Abadi RV. Visual loss and visual hallucinations in patients with age-related macular degeneration (Charles Bonnet syndrome). Invest Ophthalmol Vis Sci 2007;48(3):1416-23. PMID 17325191
- 02
- Adachi N, Watanabe T, Matsuda H, Onuma T. Hyperperfusion in the lateral temporal cortex, the striatum and the thalamus during complex visual hallucinations: single photon emission computed tomography findings in patients with Charles Bonnet syndrome. Psychiatry Clin Neurosci 2000;54(2):157-62. PMID 10803809
- 03
- Alao AO, Hanrahan B. Charles Bonnet syndrome: visual hallucination and multiple sclerosis. Int J Psychiatry Med 2003;33(2):195-9. PMID 12968834
- 04
- Alroe CJ, McIntyre JN. Visual hallucinations. The Charles Bonnet syndrome and bereavement. Med J Aust 1983;2(12):674-5. PMID 6669135
- 05
- Ashwin PT, Tsaloumas MD. Complex visual hallucinations (Charles Bonnet syndrome) in the hemianopic visual field following occipital infarction. J Neurol Sci 2007;263(1-2):184-6. PMID 17588608
- 06
- Aslan S, Ngajilo G, Nyundo A. Charles Bonnet syndrome in an elderly blind man with recurrent pituitary macroadenoma and optic nerve atrophy: a case report. Clin Case Rep 2023;11(9):e7855. PMID 37649904
- 07
- Aydin OF, Ince H, Tasdemir HA, Özyürek H. Charles Bonnet syndrome after herpes simplex encephalitis. Pediatr Neurol 2012;46(4):250-2. PMID 22490773
- 08
- Batra A, Bartels M, Wormstall H. Therapeutic options in Charles Bonnet syndrome. Acta Psychiatr Scand 1997;96(2):129-33. PMID 9272197
- 09
- Berrios GE, Brook P. The Charles Bonnet syndrome and the problem of visual perceptual disorders in the elderly. Age Ageing 1982;11(1):17-23. PMID 7041567
- 10
- Berrios GE, Brook P. Visual hallucinations and sensory delusions in the elderly. Br J Psychiatry 1984;144:662-4. PMID 6743935
- 11
- Bonnet C. Essai analytique sur les facultés de l'âme. Copenhagen and Geneva, 1769:176-7.
- 12
- Brar HK, Vaddigiri V, Scicutella A. Of illusions, hallucinations and Creutzfeldt-Jakob disease (Heidenhain's variant). J Neuropsychiatry Clin Neurosci 2005;17(1):124-6. PMID 15746494
- 13
- Braun CM, Dumont M, Duval J, Hamel-Hébert I, Godbout L. Brain modules of hallucination: an analysis of multiple patients with brain lesions. Rev Psychiatr Neurosci 2003;28(6):432-49. PMID 14631455
- 14
- Brown GC, Brown MM, Fischer DH. Photopsias: a key to diagnosis. Ophthalmology 2015;122(10):2084-94.** PMID 26249730
- 15
- Brown-Vargas D, Cienki JJ. Occipital lobe epilepsy presenting as Charles Bonnet syndrome. Am J Emerg Med 2012;30(9):2102.e5-6. PMID 22633731
- 16
- Brust JC, Behrens MM. "Release hallucinations" as the major symptom of posterior cerebral artery occlusion: a report of 2 cases. Ann Neurol 1977;2(5):432-6.** PMID 617581
- 17
- Burke W. The neural basis of Charles Bonnet hallucinations: a hypothesis. J Neurol Neurosurg Psychiatry 2002;73:535-41. PMID 12397147
- 18
- Carpenter K, Jolly JK, Bridge H. The elephant in the room: understanding the pathogenesis of Charles Bonnet syndrome. Ophthalmic Physiol Opt 2019;39(6):414-21.** PMID 31591762
- 19
- Chen CC, Liu HC. Low-dose aripiprazole resolved complex hallucinations in the left visual field after right occipital infarction (Charles Bonnet syndrome). Psychogeriatrics 2011;11(2):116-8. PMID 21707860
- 20
- Chen CS, Lin SF, Chong MY. Charles Bonnet syndrome and multiple sclerosis. Am J Psychiatry 2001;158(7):1158-9. PMID 11431243
- 21
- Choi EJ, Lee JK, Kang JK, Lee SA. Complex visual hallucinations after occipital cortical resection in a patient with epilepsy due to cortical dysplasia. Arch Neurol 2005;62(3):481-4. PMID 15767516
- 22
- Cogan DG. Visual hallucinations as release phenomena. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1973;188(2):139-50.** PMID 4543235
- 23
- Cole MG. Charles Bonnet hallucinations: a case series. Can J Psychiatry 1992;37(4):267-70. PMID 1611589
- 24
- Collerton D, Barnes J, Diederich NJ, et al. Understanding visual hallucinations: a new synthesis. Neurosci Biobehav Rev 2023;150:105208. PMID 37141962
- 25
- Contardi S, Rubboli G, Giulioni M, et al. Charles Bonnet syndrome in hemianopia, following antero-mesial temporal lobectomy for drug-resistant epilepsy. Epileptic Disord 2007;9(3):271-5. PMID 17884750
- 26
- Corlett PR, Horga G, Fletcher PC, Alderson-Day B, Schmack K, Powers AR 3rd. Hallucinations and strong priors. Trends Cogn Sci 2019;23(2):114-27. PMID 30583945
- 27
- Cox TM, ffytche DH. Negative outcome Charles Bonnet syndrome. Br J Ophthalmol 2014;98(9):1236-9. PMID 24825847
- 28
- Crumbliss KE, Taussig MJ, Jay WM. Vision rehabilitation and Charles Bonnet Syndrome. Semin Ophthalmol 2008;23(2):121-6. PMID 18320478
- 29
- daSilva Morgan K, Schumacher J, Collerton D, et al Transcranial direct current stimulation in the treatment of visual hallucinations in Charles Bonnet syndrome: a randomized placebo-controlled crossover trial. Ophthalmology 2022;129(12):1368-79. PMID 35817197
- 30
- de Morsier G. Les automatisms visuals (Hallucinations visuelles rétrochiasmatiques). Schweitz Med Wschr 1936;66:700-3.
- 31
- de Morsier G. [The Charles Bonnet syndrome: visual hallucinations in the aged without mental deficiency]. Ann Med Psychol (Paris) 1967;2(5):678-702. PMID 5585700
- 32
- Dos Reis Simoes da Silva FM, Burgos Pêgo PM, Henriques Vendrell MC, et al. Posterior reversible encephalopathy syndrome and anti-angiogenic agents: a case report. Neuroophthalmology 2011;35(1):32-7. PMID 27956931
- 33
- Echlin FA, Arnett V, Zoll J. Paroxysmal high voltage discharges from isolated and partially isolated human and animal cerebral cortex. Electroencephalogr Clin Neurophysiol 1952;4(2):147-64. PMID 13033793
- 34
- Eperjesi F, Akbarali N. Rehabilitation in Charles Bonnet syndrome: a review of treatment options. Clin Exp Optom 2004;87(3):149-52. PMID 15186205
- 35
- Eysel UT, Schweigart G, Mittmann T, et al. Reorganization in the visual cortex after retinal and cortical damage. Restor Neurol Neurosci 1999;15(2-3):153-64. PMID 12671230
- 36
- Fernandes LH, Scassellati-Sforzolini B, Spaide RF. Estrogen and visual hallucinations in a patient with Charles Bonnet syndrome. Am J Ophthalmol 2000;129(3):407. PMID 10704572
- 37
- ffytche DH. Visual hallucinations in eye disease. Curr Opin Neurol 2009;22(1):28-35. PMID 19165953
- 38
- ffytche DH, Howard RJ. The perceptual consequences of visual loss: ‘positive’ pathologies of vision. Brain 1999;122(Pt 7):1247-60.** PMID 10388791
- 39
- ffytche DH, Howard RJ, Brammer MJ, David A, Woodruff P, Williams S. The anatomy of conscious vision: an fMRI study of visual hallucinations. Nat Neurosci 1998;1(8):738-42.** PMID 10196592
- 40
- Flint AC, Loh JP, Brust JC. Vivid visual hallucinations from occipital lobe infarction. Neurology 2005;6(5):756.** PMID 16157913
- 41
- Freiman TM, Surges R, Vougioukas VI, et al. Complex visual hallucinations (Charles Bonnet syndrome) in visual field defects following cerebral surgery. Report of four cases. J Neurosurg 2004;101(5):846-53. PMID 15540925
- 42
- Frith C, Dolan RJ. Brain mechanisms associated with top-down processes in perception. Philos Trans R Soc Lond B Biol Sci 1997;352(1358):1221-30. PMID 9304688
- 43
- Gilmour G, Schreiber C, Ewing C. An examination of the relationship between low vision and Charles Bonnet syndrome. Can J Ophthalmol 2009;44(1):49-52. PMID 19169313
- 44
- Gold K, Rabins PV. Isolated visual hallucinations and the Charles Bonnet syndrome: a review of the literature and presentation of six cases. Compr Psychiatry 1989;30(1):90-8. PMID 2647403
- 45
- Gooriah R, Dafalla BE, Tun S, Venugopalan TC, Lwin KK. Visual hallucinations: an unusual manifestation of sporadic Creutzfeldt-Jakob disease termed the 'Heidenhain variant'. J Neurol 2014;261(11):2228-9. PMID 25287018
- 46
- Gruter T, Ayzenberg I, Gold R, Bornke C. Charles Bonnet syndrome successfully treated with levetiracetam. J Neurol 2016;263(9):1872-5. PMID 27485168
- 47
- Hahamy A, Wilf M, Rosin B, Behrmann M, Malach R. How do the blind 'see'? The role of spontaneous brain activity in self-generated perception. Brain 2021;144(1):340-53. PMID 33367630
- 48
- Hamedani AG, Pelak VS. The Charles Bonnet syndrome: a systematic review of diagnostic criteria. Curr Treat Options Neurol 2019;21(9):41. Erratum in: Curr Treat Options Neurol 2019;21(10):52. PMID 31342218
- 49
- Hamedani AG, Thibault DP, Shea JA, Willis AW. Self-reported vision and hallucinations in older adults: results from two longitudinal US health surveys. Age Ageing 2020;49(5):843-9. PMID 32253434
- 50
- Hanyu H, Takasaki A, Sato T, Akai T, Iwamoto T. Is Charles Bonnet syndrome an early stage of dementia with Lewy bodies. J Am Geriatr Soc 2008;56(9):1763-4. PMID 19166452
- 51
- Hartney KE, Catalano G, Catalano MC. Charles Bonnet syndrome: are medications necessary. J Psychiatr Pract 2011;17(2):137-41.** PMID 21430494
- 52
- Hawatmeh A, Studyvin S, Al-Halawani M, Amireh S, Thawabi M. Posterior reversible encephalopathy syndrome associated with left horizontal gaze palsy. Ann Transl Med 2017;5(5):104. PMID 28361069
- 53
- Hedges TR Jr. Charles Bonnet, his life, and his syndrome. Surv Ophthalmol 2007;52(1):111-4. PMID 17212994
- 54
- Heitman JD. Thurber lost most of his eyesight to a tragic childhood accident and grew up to see the world in a bizarre and hilarious light. Available at: http://www.neh.gov/humanities. Accessed January 12, 2016.
- 55
- Henderson WR, Smyth GE. Phantom limbs. J Neurol Neurosurg Psychiatry 1948;11(2):88-112. PMID 18861109
- 56
- Heron W. The pathology of boredom. Sci Am 1957;196:52-6.
- 57
- Heron W, Doane BK, Scott TH. Visual disturbances after prolonged perceptual isolation. Can J Psychol 1956;10(1):13-8. PMID 13293922
- 58
- Hori H, Terao T, Shiraishi Y, Nakamura J. Treatment of Charles Bonnet syndrome with valproate. Int Clin Psychopharmacol 2000;15(2):117-9. PMID 10759344
- 59
- Hou Y, Zhang Y. The prevalence and clinical characteristics of Charles Bonnet syndrome in Chinese patients. Gen Hosp Psychiatry 2012;34(5):566-70. PMID 22717087
- 60
- Jackson ML, Bassett KL. The natural history of the Charles Bonnet Syndrome. Do the hallucinations go away. Eye (Lond) 2010;24(7):1303-4. PMID 20150924
- 61
- Jackson TE, Madge SN. Acute Charles Bonnet syndrome secondary to eye patching. Gen Hosp Psychiatry 2011;33(3):303.e1-3. PMID 21601737
- 62
- Jacob A, Prasad S, Boggild M, Chandratre S. Charles Bonnet syndrome--elderly people and visual hallucinations. BMJ 2004;328(7455):1552-4. PMID 15217875
- 63
- Jang JW, Youn YC, Seok JW, et al. Hypermetabolism in the left thalamus and right inferior temporal area on positron emission tomography-statistical parametric mapping (PET-SPM) in a patient with Charles Bonnet syndrome resolving after treatment with valproic acid. J Clin Neurosci 2011;18(8):1130-2. PMID 21700465
- 64
- Jones L, Ditzel-Finn L, Enoch J, Moosajee M. An overview of psychological and social factors in Charles Bonnet syndrome. Ther Adv Ophthalmol 2021;13:25158414211034715. PMID 34377938
- 65
- Jones L, Moosajee M. Visual hallucinations and sight loss in children and young adults: a retrospective case series of Charles Bonnet syndrome. Br J Ophthalmol 2021;105(11):1604-09. PMID 32933935
- 66
- Jurisic D, Sesar I, Ćavar I, Sesar A, Živković M, Ćurković M. Hallucinatory experiences in visually impaired individuals: Charles Bonnet syndrome - implications for research and clinical practice. Psychiatr Danub 2018;30(2):122-8. PMID 29930220
- 67
- Kaeser PF, Borruat FX. Acute reversible Charles Bonnet syndrome precipitated by sudden severe anemia. Eur J Ophthalmol 2009;19(3):494-5. PMID 19396804
- 68
- Kazui H, Ishii R, Yoshida T, et al. Neuroimaging studies in patients with Charles Bonnet Syndrome. Psychogeriatrics 2009;9(2):77-84. PMID 19604330
- 69
- Khadavi NM, Lew H, Goldberg RA, Mancini R. A case of acute reversible Charles Bonnet syndrome following postsurgical unilateral eye patch placement. Ophthal Plast Reconstr Surg 2010;26(4):302-4. PMID 20551853
- 70
- Khan JC, Shahid H, Thurlby DA, Yates JR, Moore AT. Charles Bonnet syndrome in age-related macular degeneration: the nature and frequency of images in subjects with end-stage disease. Ophthalmic Epidemiol 2008;15(3):202-8. PMID 18569816
- 71
- Kinoshita Y, Tsuchiya M, Kawakami N, Furukawa TA, Kingdon D. Hallucinations in visually impaired individuals: an analysis of the National Comorbidity Survey Replication. Soc Psychiatry Psychiatr Epidemiol 2009;44(2):104-8. PMID 18661281
- 72
- Kolmel HW. Complex visual hallucinations in the hemianopic field. J Neurol Neurosurg Psychiatry 1985;48(1):29-38. PMID 3973619
- 73
- Kropp S, Schulz-Schaeffer WJ, Finkenstaedt M, et al. The Heidenhain variant of Creutzfeldt-Jakob disease. Arch Neurol 1999;56(1):55-61. PMID 9923761
- 74
- Kumral E, Uluakay A, Dönmez İ. Charles Bonnet syndrome in a patient with right medial occipital lobe infarction: epileptic or deafferentation phenomenon? Neurologist 2015;20(1):13-5. PMID 26185956
- 75
- Lalji A, Izbudak I, Birnbaum J. Cortical blindness and not optic neuritis as a cause of vision loss in a Sjögren's syndrome (SS) patient with the neuromyelitis optica spectrum disorder (NMOSD): Challenges of ascribing demyelinating syndromes to SS: a case report. Medicine (Baltimore) 2017;96(34):e7454. PMID 28834867
- 76
- Lance JW. Simple formed hallucinations confined to the area of a specific visual field defect. Brain 1976;99(4):719-34.** PMID 828866
- 77
- Lang UE, Stogowski D, Schulze D, et al. Charles Bonnet Syndrome: successful treatment of visual hallucinations due to vision loss with selective serotonin reuptake inhibitors. J Psychopharmacol 2007;21(5):553-5. PMID 17446204
- 78
- Lanska DJ, Lanska MJ. Visual "release" hallucinations in juvenile neuronal ceroid lipofuscinosis. Pediatr Neurol 1993;9(4):316-7.** PMID 8216547
- 79
- Lanska DJ, Lanska MJ, Mendez MF. Brainstem auditory hallucinosis. Neurology 1987;37(10):1685. PMID 3658177
- 80
- Leandro JE, Beato J, Pedrosa AC, et al. The Charles Bonnet syndrome in patients with neovascular age-related macular degeneration: association with proton pump inhibitors. Invest Ophthalmol Vis Sci 2017;58(10):4138-42. PMID 28829845
- 81
- Lomo T, Singh A, Peters D. Three cases of Charles Bonnet Syndrome in patients with advanced glaucomatous visual field loss but preserved visual acuity. Acta Ophthalmol 2021;99(4):448-51. PMID 32918400
- 82
- Manford M, Andermann F. Complex visual hallucinations. Clinical and neurobiological insights. Brain 1998;121(Pt 10):1819-40. PMID 9798740
- 83
- Martinelli F, Perez C, Caetta F, Obadia M, Savatovsky J, Chokron S. Neuroanatomic correlates of visual hallucinations in poststroke hemianopic patients. Neurology 2020;94(18):e1885-91. PMID 32253350
- 84
- Melzack R, Bromage PR. Experimental phantom limbs. Exp Neurol 1973;39(2):261-9. PMID 4702820
- 85
- Menon GJ, Rahman I, Menon SJ, Dutton GN. Complex visual hallucinations in the visually impaired: the Charles Bonnet Syndrome. Surv Ophthalmol 2003;48(1):58-72.** PMID 12559327
- 86
- Mewasingh LD, Kornreich C, Christiaens F, Christophe C, Dan B. Pediatric phantom vision (Charles Bonnet) syndrome. Pediatr Neurol 2002;26(2):143-5. PMID 11897480
- 87
- Meyer CH, Mennel S, Hörle S, Schmidt JC. Visual hallucinations after intravitreal injection of bevacizumab in vascular age-related macular degeneration. Am J Ophthalmol 2007;143(1):169-70. PMID 17188061
- 88
- Nadarajah J. Visual hallucinations and macular degeneration: an example of the Charles Bonnet syndrome. Aust N Z J Ophthalmol 1998;26(1):63-5. PMID 9524035
- 89
- Nair AG, Nair AG, Shah BR, Gandhi RA. Seeing the unseen: Charles Bonnet syndrome revisited. Psychogeriatrics 2015;15(3):204-8. PMID 25515178
- 90
- Nalcaci S, İlim O, Oztas Z, Akkin C, Acarer A, Afrashi F, Mentes J. The prevalence and characteristics of Charles Bonnet syndrome in Turkish patients with retinal disease. Ophthalmologica 2016;236(1):48-52. PMID 27188990
- 91
- Needham WE, Taylor RE. Atypical Charles Bonnet hallucinations: an elf in the woodshed, a spirit of evil, and the cowboy malefactors. J Nerv Ment Dis 2000;188(2):108-15. PMID 10695839
- 92
- Nesher R, Nesher G, Epstein E, Assia E. Charles Bonnet syndrome in glaucoma patients with low vision. J Glaucoma 2001;10(5):396-400. PMID 11711837
- 93
- Ossola M, Romani A, Tavazzi E, Pichiecchio A, Galimberti CA. Epileptic mechanisms in Charles Bonnet syndrome. Epilepsy Behav 2010;18(1-2):119-22. PMID 20471325
- 94
- Ovchinnikov A, Andereggen L, Rogers S, Gschwind M. Visual hallucinations after resection of cerebral metastases: two patients with complex phantom images. Strahlenther Onkol 2024. PMID 38453698
- 95
- Pachalska M, Kurzbauer H, MacQueen BD, Formińska-Kapuścik M, Herman-Sucharska I. Neuropsychological features of rapidly progressive dementia in a patient with an atypical presentation of Creutzfeldt-Jakob Disease. Med Sci Monit 2001;7(6):1307-15. PMID 11687748
- 96
- Pang L. Hallucinations experienced by visually impaired: Charles Bonnet syndrome. Optom Vis Sci 2016;93(12):1466-78. PMID 27529611
- 97
- Parr T, Rees G, Friston KJ. Computational neuropsychology and Bayesian inference. Front Hum Neurosci 2018;12:61. PMID 29527157
- 98
- Paulig M, Mentrup H. Charles Bonnet's syndrome: complete remission of complex visual hallucinations treated by gabapentin. J Neurol Neurosurg Psychiatry 2005;70(6):813-4. PMID 11430294
- 99
- Peters D, Molander S, Lomo T, Singh A. Charles Bonnet syndrome in patients with open-angle glaucoma: prevalence and correlation to visual field loss. Ophthalmol Glaucoma 2022;5(3):337-44. PMID 34688955
- 100
- Plesnicar BK, Zalar B, Bocic MB. The Charles Bonnet syndrome: a case report. Wien Klin Wochenschr 2004;116 Suppl 2:75-7. PMID 15506317
- 101
- Pliskin NH, Kiolbasa TA, Towle VL, et al. Charles Bonnet syndrome: an early marker for dementia. J Am Geriatr Soc 1996;44(9):1055-61. PMID 8790230
- 102
- Plummer C, Kleinitz A, Vroomen P, Watts R. Of Roman chariots and goats in overcoats: the syndrome of Charles Bonnet. J Clin Neurosci 2007;14(8):709-14. PMID 17428664
- 103
- Proulx AA, Strong MJ, Nicolle DA. Creutzfeldt-Jakob disease presenting with visual manifestations. Can J Ophthalmol 2008;43(5):591-5. PMID 18982039
- 104
- Rahman I, Fernando B, Harrison M. Charles Bonnet syndrome and brimonidine: comments. Br J Ophthalmol 2004;88(5):724. PMID 15090439
- 105
- Ramachandran VS, Blakeslee S. Phantoms in the brain: probing the mysteries of the human mind. New York: William Morrow, 1998.
- 106
- Randeblad P, Singh A, Peters D. Charles Bonnet syndrome adversely affects vision-related quality of life in patients with glaucoma. Ophthalmol Glaucoma 2024;7(1):30-6. PMID 37429533
- 107
- Ranen NG, Pasternak RE, Rovner BW. Cisapride in the treatment of visual hallucinations caused by vision loss: the Charles Bonnet syndrome. Am J Geriatr Psychiatry 1999;7(3):264-6. PMID 10438699
- 108
- Rao V. Charles Bonnet syndrome, time to drop the name. Int J Geriatr Psychiatry 1997;12(3):413. PMID 9152731
- 109
- Razavi M, Jones RD, Manzel K, Fattal D, Rizzo M. Steroid-responsive Charles Bonnet syndrome in temporal arteritis. J Neuropsychiatry Clin Neurosci 2004;16(4):505-8. PMID 15616179
- 110
- Reeder RR, Sala G, van Leeuwen TM. A novel model of divergent predictive perception. Neurosci Conscious 2024;2024(1):niae006. PMID 38348335
- 111
- Reichert DP, Seriès P, Storkey AJ. Charles Bonnet syndrome: evidence for a generative model in the cortex. PLoS Comput Biol 2013;9(7):e1003134. PMID 23874177
- 112
- Rojas LC, Gurnani B. Charles Bonnet syndrome. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing, 2024. PMID 36256781
- 113
- Russell G, Harper R, Allen H, Baldwin R, Burns A. Cognitive impairment and Charles Bonnet syndrome: a prospective study. Int J Geriatr Psychiatry 2018;33(1):39-46. PMID 28117918
- 114
- Santangelo M, Pocchiari M, Parchi P. Revisiting the Heidenhain variant of Creutzfeldt-Jakob disease: evidence for prion type variability influencing clinical course and laboratory findings. J Alzheimers Dis 2016;50(2):465-76. PMID 26682685
- 115
- Santhouse AM, Howard RJ, ffytche DH. Visual hallucinatory syndromes and the anatomy of the visual brain. Brain 2000;123(Pt 10):2055-64.** PMID 11004123
- 116
- Santos-Bueso E, Sáenz-Francés F, Serrador-García M, et al. Prevalence and clinical characteristics of Charles Bonnet syndrome in Madrid, Spain. Eur J Ophthalmol 2014;24(6):960-3. PMID 24846623
- 117
- Santos-Bueso E, Serrador-García M, Sáenz-Francés F, et al. Charles Bonnet syndrome in a child with congenital glaucoma. Arch Soc Esp Oftalmol 2017;92(8):398-400. PMID 28038923
- 118
- Sasaki H, Fujimoto Y, Ima H, Kageyama Y. Visualization of hypermetabolism in the ventral visual pathway by FDG-PET in the Charles Bonnet syndrome. Clin Neurol Neurosurg. 2021;208:106832.** PMID 34329811
- 119
- Satgunam P, Sumalini R, Chittapu G, Pamarthi G. Screening for Charles Bonnet syndrome: Should the definition be reconsidered? Indian J Ophthalmol 2019;67(7):1127-32. PMID 31238427
- 120
- Schadlu AP, Schadlu R, Shepherd JB 3rd. Charles Bonnet syndrome: a review. Curr Opin Ophthalmol 2009;20(3):219-22. PMID 19349864
- 121
- Schmid FR, Kriegleder MF. Explanatory power by vagueness. Challenges to the strong prior hypothesis on hallucinations exemplified by the Charles-Bonnet-Syndrome. Conscious Cogn 2024;117:103620. PMID 38104388
- 122
- Schultz G, Melzack R. The Charles Bonnet syndrome: 'phantom visual images'. Perception 1991;20(6):809-25. PMID 1816537
- 123
- Schultz G, Melzack R. Visual hallucinations and mental state. A study of 14 Charles Bonnet syndrome hallucinators. J Nerv Ment Dis 1993;181(10):639-43.** PMID 8409963
- 124
- Schultz G, Needham W, Taylor R, Shindell S, Melzack R. Properties of complex hallucinations associated with deficits in vision. Perception 1996;25(6):715-26. PMID 8888303
- 125
- Schwartz TL, Vahgei L. Charles Bonnet syndrome in children. J AAPOS 1998;2(5):310-3. PMID 10646756
- 126
- Segers K. Charles Bonnet syndrome disappearing with carbamazepine and valproic acid but not with levetiracetam. Acta Neurol Belg 2009;109(1):42-3. PMID 19402573
- 127
- Serrador-García M, Santos-Bueso E, Sáenz-Francés F, Díaz-Valle D, Martínez-De-La-Casa-Borrelia JM, García-Feijóo J. Charles Bonnet plus syndrome: apropos of a case. Eur J Ophthalmol 2012;22(5):836-9. PMID 22427145
- 128
- Shiraishi Y, Terao T, Ibi K, Nakamura J, Tawara A. Charles Bonnet syndrome and visual acuity--the involvement of dynamic or acute sensory deprivation. Eur Arch Psychiatry Clin Neurosci 2004a;254(6):362-4. PMID 15538606
- 129
- Shiraishi Y, Terao T, Ibi K, Nakamura J, Tawara A. The rarity of Charles Bonnet syndrome. J Psychiatr Res 2004b;38(2):207-13. PMID 14757336
- 130
- Siatkowski RM, Zimmer B, Rosenberg PR. The Charles Bonnet syndrome. Visual perceptive dysfunction in sensory deprivation. J Clin Neuroophthalmol 1990;10(3):215-8.** PMID 2144541
- 131
- Singh A, Sørensen TL. Charles Bonnet syndrome improves when treatment is effective in age-related macular degeneration. Br J Ophthalmol 2011;95(2):291-2. PMID 20733019
- 132
- Singh A, Sørensen TL. The prevalence and clinical characteristics of Charles Bonnet Syndrome in Danish patients with neovascular age-related macular degeneration. Acta Ophthalmol 2012;90(5):476-80. PMID 21106047
- 133
- Sokhi D, Yakub F, Sharma K, Waa S, Mativo P. Heidenhain variant of sporadic Creutzfeldt-Jakob disease: first reported case from East Africa. Int Med Case Rep J 2021;14:39-44. PMID 33564270
- 134
- Sonnenblick M, Nesher R, Rozenman Y, Nesher G. Charles Bonnet syndrome in temporal arteritis. J Rheumatol 1995;22(8):1596-7. PMID 7473492
- 135
- Subhi Y, Schmidt DC, Bach-Holm D, Kolko M, Singh A. Prevalence of Charles Bonnet syndrome in patients with glaucoma: a systematic review with meta-analyses. Acta Ophthalmol 2021;99(2):128-33. PMID 32749787
- 136
- Sy AJ, Gochioco DC. Charles Bonnet syndrome as sequelae of occipital lobe infarct with hemorrhagic conversion: a case report. Cureus 2023;15(12):e50472. PMID 38222233
- 137
- Tan CS, Eong KG. Charles Bonnet syndrome: hallucinations may not be what they seem. Clin Exp Optom 2004;87(6):405-6. PMID 15575817
- 138
- Tan CS, Lim VS, Ho DY, Yeo E, Ng BY, Au Eong KG. Charles Bonnet syndrome in Asian patients in a tertiary ophthalmic centre. Br J Ophthalmol 2004;88(10):1325-9. PMID 15377560
- 139
- Tan CS, Sabel BA. Charles Bonnet syndrome after occipital cortical resection for cortical dysplasia may be related to denervation supersensitivity. Arch Neurol 2005;62(9):1479-80. PMID 16157761
- 140
- Tan CS, Sabel BA, Goh KY. Visual hallucinations during visual recovery after central retinal artery occlusion. Arch Neurol 2006;63(4):598-600. PMID 16606776
- 141
- Teunisse RJ, Cruysberg JR, Hoefnagels WH, Kuin Y, Verbeek AL, Zitman FG. Social and psychological characteristics of elderly visually handicapped patients with the Charles Bonnet Syndrome. Compr Psychiatry 1999;40(4):315-9. PMID 10428192
- 142
- Teunisse RJ, Cruysberg JR, Hoefnagels WH, Verbeek AL, Zitman FG. Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome. Lancet 1996;347(9004):794-7. PMID 8622335
- 143
- Teunisse RJ, Cruysberg JR, Verbeek A, Zitman FG. The Charles Bonnet syndrome: a large prospective study in The Netherlands. A study of the prevalence of the Charles Bonnet syndrome and associated factors in 500 patients attending the University Department of Ophthalmology at Nijmegen. Br J Psychiatry 1995;166(2):254-7. PMID 7728372
- 144
- Teunisse RJ, Zitman FG, Raes DC. Clinical evaluation of 14 patients with the Charles Bonnet syndrome (isolated visual hallucinations). Compr Psychiatry 1994;35(1):70-5. PMID 8149732
- 145
- Tomsak RL, Zaret CR, Weidenthal D. Charles Bonnet syndrome precipitated by brimonidine tartrate eye drops. Br J Ophthalmol 2003;87(7):917. PMID 12812898
- 146
- Tueth MJ, Cheong JA, Samander J. The Charles Bonnet syndrome: a type of organic visual hallucinosis. J Geriatr Psychiatry Neurol 1995;8(1):1-3. PMID 7710639
- 147
- Ukai S, Yamamoto M, Tanaka M, Takeda M. Treatment of typical Charles Bonnet syndrome with donepezil. Int Clin Psychopharmacol 2004;19(6):355-7. PMID 15486523
- 148
- Urriola N, Soosapilla K, Herkes G, Nogajski J. Heidenhain variant sporadic Creutzfeldt-Jakob disease diagnosed as an autoimmune encephalitis due to a false-positive GAD autoantibody. BMJ Case Rep 2019;12(5):e229018. PMID 31061195
- 149
- Vale TC, Fernandes LC, Caramelli P. Charles Bonnet syndrome: characteristics of its visual hallucinations and differential diagnosis. Arq Neuropsiquiatr 2014;72(5):333-6. PMID 24863507
- 150
- Vaphiades MS, Celesia GG, Brigell MG. Positive spontaneous visual phenomena limited to the hemianopic field in lesions of central visual pathways. Neurology 1996;47(2):408-17. PMID 8757013
- 151
- Vojnikovic B, Radeljak S, Dessardo S, Zarkovic-Palijan T, Bajek G, Linsak Z. What associates Charles Bonnet syndrome with age-related macular degeneration. Coll Antropol 2010;34 Suppl 2:45-8. PMID 21305724
- 152
- Vukicevic M, Fitzmaurice K. Butterflies and black lacy patterns: the prevalence and characteristics of Charles Bonnet hallucinations in an Australian population. Clin Experiment Ophthalmol 2008;36(7):659-65. PMID 18983551
- 153
- Wilkinson F. Auras and other hallucinations: windows on the visual brain. Prog Brain Res 2004;144:305-20. PMID 14650857
- 154
- Yang SL, Zhang LY, Zhang SF, et al. Clinical and prognostic features of Heidenhain variant of Creutzfeldt-Jakob disease: a retrospective case series study. Eur J Neurol 2022;29(8):2412-9. PMID 35506197
- 155
- Zarkali A, Adams RA, Psarras S, Leyland LA, Rees G, Weil RS. Increased weighting on prior knowledge in Lewy body-associated visual hallucinations. Brain Commun 2019;1(1):fcz007. PMID 31886459
- 156
- Zelaya JE, Al-Khoury L. Posterior reversible encephalopathy syndrome. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing, 2024. PMID 32119379
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Douglas J Lanska MD MS MSPH
Dr. Lanska of the University of Wisconsin School of Medicine and Public Health and the Medical College of Wisconsin has no relevant financial relationships to disclose.
See Profile
Patient Profile
- Age range of presentation
-
- 2 to 65+ years
- Sex preponderance
-
- Male=female
- Heredity
-
- None
- Population groups selectively affected
-
- None selectively affected
- Occupation groups selectively affected
-
- None selectively affected
ICD & OMIM codes
- ICD-10
-
- Visual hallucinations: 368.16
- ICD-11
-
- Visual hallucinations: MB27.27
- Visual release hallucinations: 9D56
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
General Neurology
Hepatic encephalopathy
Oct. 23, 2024
-
General Neurology
Bowel dysfunction in neurologic disorders
Oct. 10, 2024
-
General Neurology
Coma due to primary brainstem and diencephalic lesions
Oct. 05, 2024
-
Neuro-Ophthalmology & Neuro-Otology
Giant cell arteritis
Sep. 25, 2024
-
Neuro-Ophthalmology & Neuro-Otology
Ischemic optic neuropathy
Sep. 25, 2024
-
Neuro-Ophthalmology & Neuro-Otology
Transient visual loss
Sep. 25, 2024
-
Neuro-Oncology
Vestibular schwannoma
Sep. 19, 2024